Tscan Therapeutics Inc (TCRX)
$7.27
+0.09
(+1.25%)▲
Performance
- $7.04$7.41$7.27
3.16%
Downside
Day's Volatility :4.99%
Upside
1.89%
- $1.93$9.69$7.27
73.45%
Downside
52 Weeks Volatility :80.08%
Upside
24.97%
Returns
| Period | Tscan Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -1.91% | 0.0% |
6 Months | 43.03% | 0.0% |
1 Year | 221.97% | 0.0% |
3 Years | -25.29% | -20.2% |
Highlights
Market Capitalization | 372.2M |
Book Value | $2.57 |
Earnings Per Share (EPS) | -0.75 |
Wall Street Target Price | 12.57 |
Profit Margin | 0.0% |
Operating Margin TTM | -5542.93% |
Return On Assets TTM | -30.79% |
Return On Equity TTM | -96.32% |
Revenue TTM | 14.8M |
Revenue Per Share TTM | 0.31 |
Quarterly Revenue Growth YOY | -91.7% |
Gross Profit TTM | -46.3M |
EBITDA | -97.0M |
Diluted Eps TTM | -0.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.21 |
EPS Estimate Next Year | -1.34 |
EPS Estimate Current Quarter | -0.26 |
EPS Estimate Next Quarter | -0.25 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 72.9%
Technicals Summary
Sell
Neutral
Buy
Tscan Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Tscan Therapeutics Inc | 17.51% | 43.03% | 221.97% | -25.29% | -31.62% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Tscan Therapeutics Inc | NA | NA | NA | -1.21 | -0.96 | -0.31 | NA | 2.57 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Tscan Therapeutics Inc | Buy | $372.2M | -31.62% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Tscan Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 7.21M → 566.0K (in $), with an average decrease of 92.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -19.61M → -30.14M (in $), with an average decrease of 53.7% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 211.8%
Institutional Holdings
EcoR1 Capital, LLC
9.46%Adage Capital Partners Gp LLC
7.38%Bvf Inc
5.66%Baker Bros Advisors LP
5.27%Propel Bio Management LLC
3.95%Vanguard Group Inc
3.42%
Company Information
harnessing novel t cell systems to extend the promise of immunotherapy
Organization | Tscan Therapeutics Inc |
Employees | 161 |
CEO | Dr. Gavin MacBeath Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$7.27
+1.25%
Keyarch Acquisition Corp
$7.27
+1.25%
Connexa Sports Technologies Inc
$7.27
+1.25%
Us Value Etf
$7.27
+1.25%
First Wave Biopharma Inc
$7.27
+1.25%
Global X Msci Next Emerging
$7.27
+1.25%
Fat Projects Acquisition Corp
$7.27
+1.25%
Capital Link Global Fintech
$7.27
+1.25%
Applied Uv Inc
$7.27
+1.25%